Evidence map›Paper›PMID 34449562›Full record

ArticleCurrent issues in molecular biology2021

Application of Combined Long Amplicon Sequencing (CoLAS) for Genetic Analysis of Neurofibromatosis Type 1: A Pilot Study.

Sumihito Togi, Hiroki Ura, Yo Niida

Open access · goldAbstract read
In one paragraph

Article in Current issues in molecular biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Molecular Modelling Hurdle in the Next-Generation Sequencing Era.International journal of molecular sciences · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Sumihito TogiCenter for Clinical Genomics, Kanazawa Medical University Hospital, Uchinada, Ishikawa 920-0923, Japan.ORCID 0000-0002-3189-8111
Hiroki UraCenter for Clinical Genomics, Kanazawa Medical University Hospital, Uchinada, Ishikawa 920-0923, Japan.ORCID 0000-0002-7600-3481
Yo NiidaCenter for Clinical Genomics, Kanazawa Medical University Hospital, Uchinada, Ishikawa 920-0923, Japan.ORCID 0000-0001-5641-7962
Kanazawa Medical University · JP

Funding

Japan Society for the Promotion of Science JP19K16528Tokumori Yasumoto Memorial Trust for Researches on TSC and Related Rare Neurological Dis-eases 2019
6 · The paper itself

Abstract

Elaborate analyses of the status of gene mutations in neurofibromatosis type 1 (NF1) are still difficult nowadays due to the large gene sizes, broad mutation spectrum, and the various effects of mutations on mRNA splicing. These problems cannot be solved simply by sequencing the entire coding region using next-generation sequencing (NGS). We recently developed a new strategy, named combined long amplicon sequencing (CoLAS), which is a method for simultaneously analysing the whole genomic DNA region and, also, the full-length cDNA of the disease-causative gene with long-range PCR-based NGS. In this study, CoLAS was specifically arranged for NF1 genetic analysis, then applied to 20 patients (five previously reported and 15 newly recruited patients, including suspicious cases) for optimising the method and to verify its efficacy and benefits. Among new cases, CoLAS detected not only 10 mutations, including three unreported mutations and one mosaic mutation, but also various splicing abnormalities and allelic expression ratios quantitatively. In addition, heterozygous mapping by polymorphisms, including introns, showed copy number monitoring of the entire

Indexed as

MutationAllelesBiomarkers, TumorHigh-Throughput Nucleotide SequencingHumansNeurofibromatosis 1Pilot ProjectsPolymerase Chain ReactionRNA SplicingBiomarkers, Tumorgenetic testinglong-range PCRmultiplex PCRneurofibromatosis type 1next-generation sequencing

Identifiers

PMID34449562
PMCPMC8929138
OpenAlexW3184333926

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.